Lyell Immunopharma (NASDAQ:LYEL) Stock Rating Reaffirmed by HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 140.00% from the company’s current price.

Lyell Immunopharma Trading Down 1.6 %

Shares of LYEL opened at $2.50 on Tuesday. Lyell Immunopharma has a 12 month low of $1.32 and a 12 month high of $3.97. The firm has a fifty day simple moving average of $2.33 and a 200 day simple moving average of $2.09. The stock has a market capitalization of $637.35 million, a price-to-earnings ratio of -2.69 and a beta of -0.54.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $4.96 million. As a group, research analysts predict that Lyell Immunopharma will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in Lyell Immunopharma during the third quarter worth about $80,000. TD Asset Management Inc raised its holdings in Lyell Immunopharma by 112.1% in the 3rd quarter. TD Asset Management Inc now owns 916,232 shares of the company’s stock valued at $1,347,000 after acquiring an additional 484,316 shares during the period. Principal Financial Group Inc. grew its position in shares of Lyell Immunopharma by 13.2% in the third quarter. Principal Financial Group Inc. now owns 68,080 shares of the company’s stock valued at $100,000 after purchasing an additional 7,915 shares during the last quarter. Ieq Capital LLC acquired a new stake in Lyell Immunopharma during the 3rd quarter worth approximately $121,000. Finally, Barclays PLC boosted its stake in Lyell Immunopharma by 23.7% in the 3rd quarter. Barclays PLC now owns 245,243 shares of the company’s stock valued at $362,000 after purchasing an additional 46,975 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.